This activity will review the rationale, mechanisms of action, and indications for current FDA-approved anti-obesity pharmacotherapies, as well as explore medications that have weight-loss-promoting potential.

This activity will provide an overview of geriatric and frailty assessment tools that can assist in guiding cancer- and transplant-related decision making through the risk stratification of older individuals before therapy is initiated. Data surrounding the relationship among increased age, geriatric- and frailty-assessment results, and disease outcomes will also be explored. Key considerations in how to best incorporate these sometimes time-intensive assessments into practice will be outlined, along with discussion of how interprofessional collaboration among members of the health care team in the creation of care plans can facilitate quality care.

This session examines the cost of development and growth of these pharmaceuticals and details the specific role that specialty pharmacy plays in making these products accessible. The high costs of therapies and patient and medication management are also discussed along with the role and value of drug benefit programs.

This activity examines current data about chronic kidney disease (CKD), including its health outcomes and relationships with cardiovascular and metabolic disease. Treatment regimens aimed at delaying progression and their outcomes are reviewed, along with current knowledge regarding the pathophysiologic and genetic basis of this disease. Areas of emerging interest in research on potential new treatments targeting the causes of CKD are discussed, including genomic analysis, and their relevance to clinical care.